p73 Function is inhibited by tumor-derived p53 mutants in mammalian cells

Molecular and Cellular Biology

Volumn 19, Issue 2, 1999, Pages 1438-1449

  Di Como, Charles J ^a   Gaiddon, Christian ^a   Prives, Carol ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN P53; PROTEIN P73; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; GENETIC TRANSCRIPTION; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MAMMAL; MUTANT; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; TUMOR SUPPRESSOR GENE;

ANIMALIA; MAMMALIA; SACCHAROMYCES CEREVISIAE;

EID: 0032951530     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.19.2.1438     Document Type: Article

References (72)

1. Bargonetti, J., J. J. Manfredi, X. Chen, D. R. Marshak, and C. Prives. 1993. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 7:2565-2574.
2. Bargonetti, J., I. Reynisdottir, P. N. Friedman, and C. Prives. 1992. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev. 6:1886-1898.
3. Bayle, J. H., B. Elenbaas, and A. J. Levine. 1995. The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc. Natl. Acad. Sci. USA 92:5729-5733.
4. Brain, R., and J. R. Jenkins. 1994. Human p53 directs DNA strand reassociation and is photolabelled by 8-azido ATP. Oncogene 9:1775-1780.
5. Buckbinder, L., R. Talbott, S. Velasco-Miguel, I. Takenaka, B. Faha, B. R. Seizinger, and N. Kley. 1995. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649.
6. Candau, R., D. M. Scolnick, P. Darpino, C. Y. Ying, T. D. Halazonetis, and S. L. Berger. 1997. Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity. Oncogene 15:807-816.
7. Chang, J., D.-H. Kim, S. W. Lee, K. Y. Choi, and Y. C. Sung. 1995. Trans-activation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATA-binding protein. J. Biol. Chem. 270:25014-25019.
8. Chin, K.-V., K. Ueda, I. Pastan, and M. M. Gottesman. 1992. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255:459-462.
9. Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355.
10. Clore, G. M., J. G. Omichinski, K. Sakaguchi, N. Zambrano, H. Sakamoto, E. Appella, and A. M. Gronenborn. 1994. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 265:386-394.
11. Deb, S., C. T. Jackson, M. A. Subler, and D. W. Martin. 1992. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J. Virol. 66:6164-6170.
12. Di Como, C. J., and C. Prives. 1998. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene 16:2627-2539.
13. Farmer, G., J. Bargonetti, H. Zhu, P. Friedman, R. Prywes, and C. Prives. 1992. Wild-type p53 activates transcription in vitro. Nature 358:83-86.
14. Farmer, G., P. Friedlander, J. Colgan, J. L. Manley, and C. Prives. 1996. Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein. Nucleic Acids Res. 24:4281-4288.
15. Fields, S., and S. K. Jang. 1990. Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046-1049.
16. Flaman, J.-M., T. Frebourg, V. Moreau, F. Charbonnier, C. Martin, P. Chappuis, A.-P. Sappino, J.-L. Limacher, L. Bron, J. Benhattar, M. Tada, E. G. Van Meir, A. Estreicher, and R. D. Iggo. 1995. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl. Acad. Sci. USA 92:3963-3967.
17. Forrester, K., S. E. Lupold, V. L. Ott, C. H. Chay, V. Band, X. W. Wang, and C. C. Harris. 1995. Effects of p53 mutants on wild-type p53-mediated trans-activation are cell type dependent. Oncogene 10:2103-2111.
18. Frazier, M. W., X. He, J. Wang, Z. Gu, J. L. Cleveland, and G. P. Zambetti. 1998. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol. Cell. Biol. 18:3735-3743.
19. Friedlander, P., Y. Haupt, C. Prives, and M. Oren. 1996. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol. 16:4961-4971.
20. Friedman, P. N., X. Chen, J. Bargonetti, and C. Prives. 1993. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc. Natl. Acad. Sci. USA 90:3319-3323.
21. Gaiddon, C. B., A.-L. Monnier, L. Mercken, and J.-P. Loeffler. 1994. Genomic effects of the putative oncogene G alpha s. Chronic transcriptional activation of the c-fos proto-oncogene in endocrine cells. J. Biol. Chem. 269:22663-22671.
22. Gottlieb, T., and M. Oren. 1996. p53 in growth control and neoplasia. Biochim. Biophys. Acta 1287:77-102.
23. Gualberto, A., K. Aldape, K. Kozakiewicz, and T. Tlsty. 1998. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc. Natl. Acad. Sci. USA 95:5166-5171.
24. Guthrie, J. A., and G. R. Fink (ed.). 1991. Methods in enzymology, vol. 194. Academic Press, Inc., San Diego, Calif.
25. Hachiya, M., A. Chumakov, C. W. Miller, M. Akashi, J. Said, and H. P. Koeffler. 1994. Mutant p53 proteins behave in a dominant, negative fashion in vivo. Anticancer Res. 14:1853-1860.
26. Halazonetis, T. D., L. J. Davis, and A. N. Kandil. 1993. Wild-type p53 adopts a 'mutant'-like conformation when bound to DNA. EMBO J. 12:1021-1028.
27. Halazonetis, T. D., and A. N. Kandil. 1993. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J. 12:5057-5064.
28. Hale, A. J., C. A. Smith, L. C. Sutherland, V. E. A. Stoneman, V. L. Longthorne, A. C. Culhane, and G. T. Williams. 1996. Apoptosis: molecular regulation of cell death. Eur. J. Biochem. 236:1-26.
29. Ishioka, C., T. Frebourg, Y.-X. Yan, M. Vidal, S. H. Friend, S. Schmidt, and R. Iggo. 1993. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat. Genet. 5:124-129.
30. Jayaraman, L., K. G. K. Murthy, C. Zhu, T. Curran, S. Xanthoudakis, and C. Prives. 1997. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev. 11:558-570.
31. Jeffrey, P. D., S. Gorina, and N. P. Pavletich. 1995. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267:1498-1502.
32. Jost, C. A., M. C. Marin, and W. G. Kaelin, Jr. 1997. p73 is a human p53-related protein that can induce apoptosis. Nature 389:191-194.
33. Kaghad, M., H. Bonnet, A. yang, L. Creancier, J.-C. Biscan, A. Valent, A. Minty, P. Chalon, J.-M. Lelias, X. Dumont, P. Ferrara, F. McKeon, and D. Caput. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819.
34. Kern, S. E., K. W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman, C. Prives, and B. Vogelstein. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708-1711.
35. Kern, S. E., J. A. Pientenpol, S. Thiagalingam, A. Seymour, K. W. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830.
36. Kieser, A., H. A. Weich, G. Brandner, D. Marme, and W. Kolch. 1994. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9:963-969.
37. Ko, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054-1072.
38. Lamm, G. M., P. Steinlein, M. Cotten, and G. Christofori. 1997. A rapid, quantitative and inexpensive method for detecting apoptosis by flow cytometry in transiently transfected cells. Nucleic Acids Res. 25:4855-4857.
39. Lee, W., T. S. Harvey, Y. Yin, P. Yau, D. Litchfield, and C. H. Arrowsmith. 1994. Solution structure of the tetrameric minimum transforming domain of p53. Nat. Struct. Biol. 1:877-890.
40. Lee, Y., Y. Chen, L. S. Chang, and L. F. Johnson. 1997. Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein. Exp. Cell Res. 234:270-276.
41. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
42. Ludes-Meyers, J. H., M. A. Subler, C. V. Shivakumar, R. M. Munoz, P. Jiang, J. E. Bigger, D. R. Brown, S. P. Deb, and S. Deb. 1996. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol. Cell. Biol. 16:6009-6019.
43. Ludwig, R. L., S. Bates, and K. H. Vousden. 1996. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol. 16:4952-4960.
44. Margulies, L., and P. B. Sehgal. 1993. Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species. J. Biol. Chem. 268:15096-15100.
45. Michalovitz, D., O. Halevy, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62:671-680.
46. Miller, C. W., A. Chumakov, J. Said, D. L. Chen, A. Aslo, and H. P. Koeffler. 1993. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription. Oncogene 8:1815-1824.
47. Milner, J., and E. A. Medcalf. 1991. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65:765-774.
48. Milner, J., E. A. Medcalf, and A. C. Cook. 1991. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol. Cell. Biol. 11:12-19.
49. Miyashita, T., and J. C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
50. Osada, M., M. Ohba, C. Kawahara, C. Ishioka, R. Kanamaru, I. Katoh, Y. Ikawa, Y. Nimura, A. Nakagawara, M. Obinata, and S. Ikawa. 1998. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 4:839-843.
51. Pavletich, N. P., K. A. Chambers, and C. O. Pabo. 1993. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7:2556-2564.
52. Prabhu, N. S., K. Somasundaram, K. Satyamoorthy, M. Herlyn, and W. El-Deiry. 1998. P73β, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int. J. Oncol. 13:5-9.
53. Ptashne, M., and A. A. F. Gann. 1990. Activators and targets. Nature 346: 329-331.
54. Rainwater, R., D. Parks, M. E. Anderson, P. Tegtmeyer, and K. Mann. 1995. Role of cysteine residues in regulation of p53 function. Mol. Cell. Biol. 15:3892-3903.
55. Raycroft, L., H. Wu, and G. Lozano. 1990. Transcriptional activation by wild-type p53 but not transforming mutants of the p53 anti-oncogene. Science 249:1049-1051.
56. Raycroft, L., J. R. Schmidt, K. Yoas, M. Hao, and G. Lozano. 1991. Analysis of p53 mutants for transcriptional activity. Mol. Cell. Biol. 11:6067-6074.
57. Reed, M., B. Woelker, P. Wang, Y. Wang, M. E. Anderson, and P. Tegtmeyer. 1995. The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc. Natl. Acad. Sci. USA 92:9455-9459.
58. Rose, M. D., F. Winston, and P. Heiter. 1990. Laboratory course manual for methods in yeast genetics. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
59. Schmale, H., and C. Bamberger. 1997. A novel protein with strong homology to the tumor suppressor p53. Oncogene 15:1363-1367.
60. Senoo, M., N. Seki, M. Ohira, S. Sugano, M. Watanabe, M. Tachibana, T. Tanaka, Y. Shinkai, and H. Kato. 1998. A second p53-related protein, p73L, with high homology to p73. Biochem. Biophys. Res. Commun. 248:603-607.
61. Shaulian, E., A. Zauberman, D. Ginsberg, and M. Oren. 1992. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol. 12:5581-5592.
62. Silhavy, T. J., M. L. Berman, and L. W. Enquist. 1984. Experiments with gene fusions. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. N.Y.
63. Srivastava, S., S. Wang, Y. A. Tong, K. Pirollo, and E. H. Chang. 1993. Several mutant p53 proteins detected in cancer-prone families with LiFraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53. Oncogene 8:2449-2456.
64. Tada, M., S. Sakuma, R. D. Iggo, H. Saya, Y. Sawamura, T. Fujiwara, and J. A. Roth. 1998. Monitoring adenoviral p53 transduction efficiency by yeast functional assay. Gene Ther. 5:339-344.
65. Tsutsumi-Ishi, Y., A. Tadokoro, F. Hanaoka, and N. Tsuchida. 1995. Response of heat shock element within the human HSP70 promoter to mutated p53 genes. Cell Growth Differ. 6:1-8.
66. Ueba, T., T. Nosaka, J. A. Takahashi, F. Shibata, R. Z. Florkiewicz, B. Vogelstein, Y. Oda, H. Kikuchi, and M. Hatanaka. 1994. Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc. Natl. Acad. Sci. USA 91: 9009-9013.
67. Unger, T., J. A. Mietz, M. Scheffner, C. L. Yee, and P. M. Howley. 1993. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol. Cell. Biol. 13:5186-5194.
68. Unger, T., M. M. Nau, S. Segal, and J. D. Minna. 1992. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 11:1383-1390.
69. Vogelstein, B., and K. W. Kinzler. 1992. p53 function and dysfunction. Cell 70:523-526.
70. Walker, K. K., and A. J. Levine. 1996. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. USA 93:15335-15340.
71. Wang, Y., M. Reed, P. Wang, J. E. Stenger, G. Mayr, M. E. Anderson, J. F. Schwedes, and P. Tegtmeyer. 1993. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev. 7:2575-2586.
72. Yang, A., M. Kaghad, Y. Wang, E. Gillett, M. D. Fleming, V. Dotsch, N. C. Andrews, D. Caput, and F. McKeon. 1998. p63. a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2:305-316.